Opinion|Videos|July 1, 2026

Prophylactic Anticoagulation With Amivantamab Plus Lazertinib in EGFR+ NSCLC

Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. The prophylactic anticoagulation is particularly recommended for the first 4 months of treatment, when the risk of VTE is highest.

Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. The prophylactic anticoagulation is particularly recommended for the first 4 months of treatment, when the risk of VTE is highest.


Latest CME